Correction to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose

Allegretti, Jessica R.; Fischer, Monika; Sagi, Sashidhar; Bohm, Matthew; Fadda, Hala M.; Ranmal, Sejal R.; Budree, Shrish; Basit, Abdul W.; Glettig, Dean L.; Serna, Eva L. de la; Gentile, Amanda; Gerardin, Ylaine; Timberlake, Sonia; Sadovsky, Rotem Gura; Smith, Mark; Kassam, Zain

doi:10.1007/s10620-019-05527-4

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated by a gamma-scintigraphy study, in healthy human subjects, that the combination of a pH and bacteria trigger mechanism (Phloral™) resulted in more accurate ileocolonic targeting (Ibekwe et al 2008b, Allegretti et al 2019, acting as a fail-safe system in case one of the triggers is not activated. A novel 1600 mg 5-ASA colonic targeted formulation comprising the Phloral™ technology, embedded into the OPTICORE™ technology, (Varum et al 2020) has successfully achieved accurate colonic targeting as proven by means of gammascintigraphy (unpublished data).…”

Section: Characterisation Of Phloral™ Coated Tabletsmentioning

confidence: 99%

A dual pH and microbiota-triggered coating (Phloral™) for fail-safe colonic drug release

Varum

Freire

Fadda

et al. 2020

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Characterisation Of Phloral™ Coated Tabletsmentioning

confidence: 99%

A dual pH and microbiota-triggered coating (Phloral™) for fail-safe colonic drug release

Varum

Freire

Fadda

et al. 2020

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…6). The details of the twotrigger system (Phloral™) have been previously described (Ibekwe et al 2008b, Dodoo et al 2017, Allegretti et al 2019, Varum et al 2020.…”

Section: Opticore™ Coating -Combining a Two-trigger Outer Layer With Accelerated Release Propertiesmentioning

confidence: 99%

OPTICORE™, an innovative and accurate colonic targeting technology

Varum

Freire

Bravo

et al. 2020

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…This coating combined a polysaccharide in the same coating, to provide the enzymatic trigger and an enteric polymer Eudragit ® S and to provide pH trigger when pH = 7 was reached. The efficacy of this combined strategy was demonstrated in healthy human individuals and the system acted as an accurate and fail-safe colonic release disposition, in case one of the approaches was not activated [ 57 , 118 ]. Studies with Phloral were continued by Varum et al [ 119 ], which explored the relationship between the manufacturing process and the behavior of the coating tablets.…”

Section: Oral Cdds For Ibd Managementmentioning

confidence: 99%

New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy

Teruel

González‐Álvarez

Bermejo

et al. 2020

IJMS

View full text Add to dashboard Cite

Colonic Drug Delivery Systems (CDDS) are especially advantageous for local treatment of inflammatory bowel diseases (IBD). Site-targeted drug release allows to obtain a high drug concentration in injured tissues and less systemic adverse effects, as consequence of less/null drug absorption in small intestine. This review focused on the reported contributions in the last four years to improve the effectiveness of treatments of inflammatory bowel diseases. The work concludes that there has been an increase in the development of CDDS in which pH, specific enzymes, reactive oxygen species (ROS), or a combination of all of these triggers the release. These delivery systems demonstrated a therapeutic improvement with fewer adverse effects. Future perspectives to the treatment of this disease include the elucidation of molecular basis of IBD diseases in order to design more specific treatments, and the performance of more in vivo assays to validate the specificity and stability of the obtained systems.

show abstract

Correction to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose

Cited by 4 publications

References 0 publications

A dual pH and microbiota-triggered coating (Phloral™) for fail-safe colonic drug release

A dual pH and microbiota-triggered coating (Phloral™) for fail-safe colonic drug release

OPTICORE™, an innovative and accurate colonic targeting technology

New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy

Contact Info

Product

Resources

About